Skip to ContentSkip to Navigation
How to find us J.V. Koomen, MSc


Clinical validation of pharmacokinetic/pharmacodynamic models for propofol infusion. Response to Br J Anaesth 2021: 126: e172-4

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

Pharmacokinetic insights in individual drug response: A model-based approach to quantify individual exposure-response relationships in type 2 diabetes

Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

Individual atrasentan exposure is associated with long-term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease

Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight

Read more